Sun Pharma gets US FDA nod to market generic Uroxatral tablets

20 Jul 2011 Evaluate

Sun Pharmaceutical Industries Ltd has received the US health regulator’s nod to market Alfuzosin Hydrochloride tablets, used in the treatment of prostatic hyperplasia, in the American market. Sun Pharma, being the first-to-file an abbreviated new drug application (ANDA) for generic Uroxatral ER with a para IV certification, received 180-day marketing exclusivity. Alfuzosin Hydrochloride extended release tablets, which are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia, have annual sales of nearly $250 million in the US.crackcrack

Sun Pharma Inds. Share Price

1804.95 -13.65 (-0.75%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×